Difamilast

This study uses a matching-adjusted indirect comparison (MAIC) to explore the relative clinical efficacy and safety of difamilast versus delgocitinib in patients with atopic dermatitis (AD) in Japan. Both drugs have been proven efficacious and safe in phase 2 and 3 clinical trials, but no head-to-head trials have compared their efficacy and safety directly. The MAIC method aligns patient-level data from the difamilast trial with aggregate data from the delgocitinib trial, reducing bias in treatment comparisons. The study finds no notable statistical differences between the two treatments in terms of proportion of patients by severity, mean percentage change in mEASI at week 4, achievement of mEASI-50 and mEASI-75, and incidence of adverse events at week 4, suggesting comparable clinical efficacy and safety.